Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed changes in the pattern of dermatological diseases among Iraqi females during the COVID-19 pandemic, with increased hair loss and decreased viral infections, which may relate to pandemic-associated stress or mask-wearing.

This trial found that intradermal injections of the Hair Stimulating Complex were well-tolerated and effectively stimulated hair growth and prevented hair loss in male pattern baldness participants over 18 weeks.

In this prospective cohort study, male pattern baldness was identified as an independent predictor of prostate cancer, while the 2D:4D finger ratio was not associated with the cancer risk.

Changes in scalp bacteria are linked to female hair loss, suggesting new treatment options.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

This study observed a high prevalence of PCOS among young female-pattern hair loss patients and suggested that AMH levels might be more indicative of FPHL than traditional androgens.

This study observed that the proportion of female pattern hair loss among total alopecia cases has significantly increased over the past 20-30 years, with teenage cases rising likely due to earlier puberty.

Medical treatments like minoxidil and finasteride are important for improving hair loss and quality of life.

This study found that in Hidradenitis Suppurativa patients, the psychosocial subscale of Skindex-17 is most relevant for assessing quality of life across different severity levels, with irritation and pain becoming more pertinent as severity progresses.

This study reported that para-phenylenediamine and toluene-2,5-diamine are the main sensitizers in hair dye-related allergic contact dermatitis, with significant cross-reactivity to several other compounds.

This study found no significant genetic correlations between male pattern baldness and COVID-19 outcomes, suggesting that shared genetic factors may not explain the reported association.

This study observed that non-scarring diffuse hair loss was common in systemic lupus erythematosus patients, but did not find a significant relationship with the SLE Disease Activity Index.

This study found that follicular unit transplantation using specific techniques may improve the natural appearance of transplanted hair in patients with male-pattern hair loss.

In this study, trichoscopy was found to be an effective noninvasive tool for diagnosing female pattern hair loss at early stages, potentially eliminating the need for scalp biopsies.

In this study, 42% of healthy men aged 18-49 showed moderate to extensive male pattern hair loss, with prevalence increasing significantly with age.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

This study reported that finasteride 1 mg significantly improved hair growth in men aged 41 to 60 with predominantly vertex male pattern hair loss over 24 months compared to placebo.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This article highlights the absence of empirical research on the psychological impact of female pattern hair loss and treatment initiation in Australian women, reporting no new clinical findings.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

In this study, 1.25 mg daily finasteride for 28 weeks showed minimal increase in hair density and thickness in normoandrogenic female pattern hair loss, but no significant clinical improvement was observed.

This study found that hHbl gene expression is localized in the cortical cells of the human hair shaft and is notably high in pilomatricoma cells transitioning to hair shaft keratinocytes.

This study found that while the combination therapy of 3% minoxidil and 0.1% finasteride lotion showed greater improvement in global photographic assessments for androgenetic alopecia, hair counts did not differ significantly from minoxidil alone.

This study found that 32% of men continued finasteride use for 1 to 3 years, with many reporting poor hair growth results.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

This study found that trichoscopic parameters in male androgenetic alopecia deteriorated progressively with increasing disease severity and were significantly linked to genetic, metabolic, and psychosocial factors.

This study found topical finasteride and minoxidil both improved hair loss clinically and trichoscopically more effectively than spironolactone in women with female pattern hair loss.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.